Lumito AB publishes Quarterly Report 2, 2021
Financial overview of the second quarter and the half year Second quarter 2021, April 1 – June 30 Net sales amounted to KSEK 0 (0). Result after taxes amounted to KSEK -6 619 (-4 202). Earnings per share before and after dilution amounted to SEK -0.08 (-0.06). Cash flow from operating activities after changes in […]
Patent approved also in India
The patent describing the use of light pulses to improve the efficiency of the technique and shorten imaging times has now also been granted in India. The patent has already been approved in Europe, South Korea, Australia, China, South Africa, USA and Japan and we are awaiting approval in Canada. – The grant of the […]
Processes in place for ISO 13485 qualification
Confirmation from an independent auditing company now shows that Lumito has the processes in place to qualify for ISO 13485. The first step has been passed and the next step in the process is for the company to demonstrate that the processes are being followed in practice. The processes reflect that the company is well […]
Lumito AB Quarterly Report (1 Jan to 31 March) 2021
Significant events during the first quarter of 2021 Lumito’s advisors in the field of pathology have had the opportunity to review the company’s UCNP immunostaining of invasive breast cancer with an antibody against HER2 (the target molecule) at a high image resolution. “The signals are uniquely sharp and clear, which gives the impression of staining […]
Lumito AB publishes Quarterly Report 1, 2021
Financial overview for the first quarter January 1st to March 31st, 2021 • Net sales amounted to SEK 0 (0) thousand • Profit after tax amounted to SEK -6,825 (-2,795) thousand. • Earnings per share before and after dilution amounted to SEK -0.08 (-0.04). • Cash flow from operating activities after changes in working capital […]
Lumito publishes Year-end Report for 2020
Financial overview 2020 Financial overview of the fourth quarter, 1 October – 31 December 2020. Net sales amounted to kSEK 0 (0). Result after taxes amounted to kSEK -5,200 (-2,545). Basic and diluted earnings per share amounted to SEK -0.06 (-0.04) Cash flow from operating activities amounted to kSEK -5,198 (-3,145). Financial overview of the […]
Lumito initiates process for listing on Nasdaq First North Growth Market
The Lund-based medical device company Lumito AB has initiated a process to list the Company's shares and warrants on Nasdaq First North Growth Market. As part of this process, a conditional application for delisting from NGM Nordic SME has been submitted to NGM. The application is conditional on Nasdaq’s approval of Lumito for listing on […]
With potential to revolutionize tissue immunostaining
Picture of UCNP-stained HER2 marker in breast tissue. The colour is easily digitally edited after the image capture, which makes it possible to highlight interesting areas in each sample. The colours of the markers are digitally edited after the image capture. Lumito’s advisors in the field of pathology have now had the opportunity to review […]
New CEO of Lumito AB
The Board of Directors of Lumito AB has resolved to appoint Mattias Lundin CEO of the Company. He will take office on March 8, 2021. The Board of Directors of Lumito AB has resolved to appoint Mattias Lundin CEO of the Company. He will take office on March 8, 2021. Mattias Lundin is currently the […]
Quarterly report 3, 2020, Lumito AB (publ)
Financial overview of the third quarter July 1st – September 30th, 2020 Net sales amounted to SEK 0 (0) thousand. Profit after tax amounted to SEK -3,851 (-1,325) thousand. Earnings per share before and after dilution amounted to SEK -0.05 (-0.02). Cash flow from operating activities amounted to SEK -3,850 (-1,325) thousand. Nine months, January […]
